BTIG Reiterates Buy on Serina Therapeutics, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.6%

Neg 0% Neu 87.6% Pos 0%

BTIG analyst Thomas Shrader reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $8 price target.

Comments

No comments yet. Be the first!